Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

Recruiting now · Not applicable

Conditions studied: Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus, Dehydration

In brief

This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.

Key facts

Study ID

NCT07641361

Run by

State University of New York at Buffalo

People needed

30

Starts

2026-06-15

Expected to finish

2027-02-01

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18-60
• Recently prescribed a GLP-1RA (within one week of prescription)
• Fluent in English
• Willing to complete the study protocol

You may not qualify if…

• Children and adults > 60 years of age
• Those not taking a GLP-1RA
• Those who have been on a GLP-1RA longer than one week
• Not fluent in English
• Those who are pregnant or planning on becoming pregnant during the duration of the study
• Unwilling to comply with study protocol
• People with cardiac implants

Where it is running

• State University of New York at Buffalo, South Campus — Buffalo, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.